You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameL-Alanine
Accession NumberDB00160  (NUTR00013)
Typesmall molecule
Groupsapproved, nutraceutical
Description

A non-essential amino acid that occurs in high levels in its free state in plasma. It is produced from pyruvate by transamination. It is involved in sugar and acid metabolism, increases immunity, and provides energy for muscle tissue, brain, and the central nervous system. [PubChem]

Structure
Thumb
Synonyms
SynonymLanguageCode
(2S)-2-Aminopropanoic acidNot AvailableNot Available
(S)-2-Aminopropanoic acidNot AvailableNot Available
(S)-AlanineNot AvailableNot Available
ALANot AvailableNot Available
AlanineNot AvailableNot Available
L-2-Aminopropionic acidNot AvailableNot Available
L-alpha-AlanineNot AvailableNot Available
L-α-alanineNot AvailableNot Available
SaltsNot Available
Brand namesNot Available
Brand mixtures
Brand NameIngredients
AminosynGlycine + Histidine + L-Alanine + L-Arginine + L-Isoleucine + L-Leucine + L-Lysine (L-Lysine Acetate) + L-Phenylalanine + L-Proline + L-Threonine + L-Tyrosine + L-Valine + Methionine + Serine + Tryptophan
Aminosyn IIGlutamic Acid + Glycine + Histidine + L-Alanine + L-Arginine + L-Aspartic Acid + L-Isoleucine + L-Leucine + L-Lysine (L-Lysine Acetate) + L-Phenylalanine + L-Proline + L-Threonine + L-Valine + Methionine + N-Acetyl-L-Tyrosine + Serine + Tryptophan
PrimeneGlutamic Acid + Glycine + Histidine + L-Alanine + L-Arginine + L-Aspartic Acid + L-Cysteine + L-Isoleucine + L-Leucine + L-Lysine + L-Ornithine Dihydrochloride + L-Phenylalanine + L-Proline + L-Threonine + L-Tyrosine + L-Valine + Methionine + Serine + Taurine + Tryptophan
Renamin (Amino Acids) InjectionGlycine + Histidine + L-Alanine + L-Arginine + L-Isoleucine + L-Leucine + L-Lysine Hydrochloride + L-Phenylalanine + L-Proline + L-Threonine + L-Tyrosine + L-Valine + Methionine + Serine + Tryptophan
Travasol Amino Acid Injection With ElectrolytesDextrose + Glycine + Histidine + L-Alanine + L-Arginine + L-Isoleucine + L-Leucine + L-Lysine (L-Lysine Hydrochloride) + L-Phenylalanine + L-Proline + L-Threonine + L-Tyrosine + L-Valine + Magnesium Chloride + Methionine + Potassium Phosphate Dibasic + Serine + Sodium Acetate + Sodium Chloride + Tryptophan
Travasol Amino Acid Injection Without ElectrolytesDextrose + Glycine + Histidine + L-Alanine + L-Arginine + L-Isoleucine + L-Leucine Hydrochloride + L-Lysine Hydrochloride + L-Phenylalanine Hydrochloride + L-Proline + L-Threonine + L-Tyrosine + L-Valine + Methionine + Tryptophan
Categories
CAS number56-41-7
WeightAverage: 89.0932
Monoisotopic: 89.047678473
Chemical FormulaC3H7NO2
InChI KeyQNAYBMKLOCPYGJ-RUOZJJLTNA-N
InChI
InChI=1/C3H7NO2/c1-2(4)3(5)6/h2H,4H2,1H3,(H,5,6)/t2-/s2
IUPAC Name
(2S)-2-aminopropanoic acid
SMILES
C[C@H](N)C(O)=O
Mass Specshow(6.76 KB)
Taxonomy
KingdomOrganic Compounds
SuperclassOrganic Acids and Derivatives
ClassCarboxylic Acids and Derivatives
SubclassAmino Acids, Peptides, and Analogues
Direct parentAlpha Amino Acids and Derivatives
Alternative parentsPolyamines; Enolates; Carboxylic Acids; Monoalkylamines
Substituentscarboxylic acid; enolate; polyamine; primary amine; amine; primary aliphatic amine; organonitrogen compound
Classification descriptionThis compound belongs to the alpha amino acids and derivatives. These are amino acids in which the amino group is attached to the carbon atom immediately adjacent to the carboxylate group (alpha carbon), or a derivative thereof.
Pharmacology
IndicationUsed for protein synthesis.
PharmacodynamicsIs an important source of energy for muscle tissue, the brain and central nervous system; strengthens the immune system by producing antibodies; helps in the metabolism of sugars and organic acids.
Mechanism of actionL-Alanine is a non-essential amino acid that occurs in high levels in its free state in plasma. It is produced from pyruvate by transamination. It is involved in sugar and acid metabolism, increases immunity, and provides energy for muscle tissue, brain, and the central nervous system. BCAAs are used as a source of energy for muscle cells. During prolonged exercise, BCAAs are released from skeletal muscles and their carbon backbones are used as fuel, while their nitrogen portion is used to form another amino acid, Alanine. Alanine is then converted to Glucose by the liver. This form of energy production is called the Alanine-Glucose cycle, and it plays a major role in maintaining the body's blood sugar balance.
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
Metabolism
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
2-Hydroxyglutric Aciduria (D And L Form)DiseaseSMP00136
3-Phosphoglycerate dehydrogenase deficiencyDiseaseSMP00721
4-Hydroxybutyric Aciduria/Succinic Semialdehyde Dehydrogenase DeficiencyDiseaseSMP00243
Selenoamino Acid MetabolismMetabolicSMP00029
Lactic AcidemiaDiseaseSMP00313
Argininosuccinic AciduriaDiseaseSMP00003
Clindamycin Action PathwayDrug actionSMP00249
Oxytetracycline Action PathwayDrug actionSMP00293
Clarithromycin Action PathwayDrug actionSMP00248
Clomocycline Action PathwayDrug actionSMP00262
Tigecycline Action PathwayDrug actionSMP00712
Rolitetracycline Action PathwayDrug actionSMP00726
Roxithromycin Action PathwayDrug actionSMP00251
Tetracycline Action PathwayDrug actionSMP00294
Streptomycin Action PathwayDrug actionSMP00259
Doxycycline Action PathwayDrug actionSMP00291
Amikacin Action PathwayDrug actionSMP00253
Paromomycin Action PathwayDrug actionSMP00714
Spectinomycin Action PathwayDrug actionSMP00258
Telithromycin Action PathwayDrug actionSMP00252
Kanamycin Action PathwayDrug actionSMP00255
Chloramphenicol Action PathwayDrug actionSMP00729
Minocycline Action PathwayDrug actionSMP00292
Neomycin Action PathwayDrug actionSMP00256
Netilmicin Action PathwayDrug actionSMP00257
Gentamicin Action PathwayDrug actionSMP00254
Tobramycin Action PathwayDrug actionSMP00711
Arbekacin Action PathwayDrug actionSMP00713
Josamycin Action PathwayDrug actionSMP00731
Demeclocycline Action PathwayDrug actionSMP00290
Erythromycin Action PathwayDrug actionSMP00250
Lymecycline Action PathwayDrug actionSMP00295
Azithromycin Action PathwayDrug actionSMP00247
Lincomycin Action PathwayDrug actionSMP00728
Methacycline Action PathwayDrug actionSMP00727
Troleandomycin Action PathwayDrug actionSMP00730
Alanine MetabolismMetabolicSMP00055
Glucose-Alanine CycleMetabolicSMP00127
Glycine and Serine MetabolismMetabolicSMP00004
ArgininemiaDiseaseSMP00357
Carbamoyl Phosphate Synthetase DeficiencyDiseaseSMP00002
Pyruvate Carboxylase DeficiencyDiseaseSMP00350
Citrullinemia Type IDiseaseSMP00001
Urea CycleMetabolicSMP00059
Ornithine Transcarbamylase Deficiency (OTC Deficiency)DiseaseSMP00205
Dihydropyrimidine Dehydrogenase Deficiency (DHPD)DiseaseSMP00179
Succinic semialdehyde dehydrogenase deficiencyDiseaseSMP00567
Dimethylglycine Dehydrogenase DeficiencyDiseaseSMP00242
DimethylglycinuriaDiseaseSMP00484
Glutamate MetabolismMetabolicSMP00072
HomocarnosinosisDiseaseSMP00385
Hyperinsulinism-Hyperammonemia SyndromeDiseaseSMP00339
Non Ketotic HyperglycinemiaDiseaseSMP00223
Hyperglycinemia, non-ketoticDiseaseSMP00485
Primary Hyperoxaluria Type IDiseaseSMP00352
Tryptophan MetabolismMetabolicSMP00063
SarcosinemiaDiseaseSMP00244
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
Property Value Probability
Human Intestinal Absorption Not Available Not Available
Blood Brain Barrier Not Available Not Available
Caco-2 permeable Not Available Not Available
P-glycoprotein substrate Not Available Not Available
P-glycoprotein inhibitor I Not Available Not Available
P-glycoprotein inhibitor II Not Available Not Available
Renal organic cation transporter Not Available Not Available
CYP450 2C9 substrate Not Available Not Available
CYP450 2D6 substrate Not Available Not Available
CYP450 3A4 substrate Not Available Not Available
CYP450 1A2 substrate Not Available Not Available
CYP450 2C9 substrate Not Available Not Available
CYP450 2D6 substrate Not Available Not Available
CYP450 2C19 substrate Not Available Not Available
CYP450 3A4 substrate Not Available Not Available
CYP450 inhibitory promiscuity Not Available Not Available
Ames test Not Available Not Available
Carcinogenicity Not Available Not Available
Biodegradation Not Available Not Available
Rat acute toxicity Not Available Not applicable
hERG inhibition (predictor I) Not Available Not Available
hERG inhibition (predictor II) Not Available Not Available
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage formsNot Available
Prices
Unit descriptionCostUnit
L-alanine powder2.35USDg
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
Statesolid
Experimental Properties
PropertyValueSource
melting point300 dec °CPhysProp
water solubility1.64E+005 mg/L (at 25 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP-2.85SANGSTER (1994)
pKa2.34 (at 25 °C)KORTUM,G ET AL (1961)
Predicted Properties
PropertyValueSource
water solubility4.47e+02 g/lALOGPS
logP-3ALOGPS
logP-2.8ChemAxon
logS0.7ALOGPS
pKa (strongest acidic)2.47ChemAxon
pKa (strongest basic)9.48ChemAxon
physiological charge0ChemAxon
hydrogen acceptor count3ChemAxon
hydrogen donor count2ChemAxon
polar surface area63.32ChemAxon
rotatable bond count1ChemAxon
refractivity20.5ChemAxon
polarizability8.49ChemAxon
number of rings0ChemAxon
bioavailability1ChemAxon
rule of fiveYesChemAxon
Ghose filterNoChemAxon
Veber's ruleNoChemAxon
MDDR-like ruleNoChemAxon
Spectra
SpectraNot Available
References
Synthesis Reference

Daniel T. Belmont, Valerie Hendrickson, Mark J. Hoekman, “Process for the preparation of an L-alanine compound.” U.S. Patent US5268483, issued October, 1953.

US5268483
General ReferenceNot Available
External Links
ResourceLink
KEGG CompoundC01401
ChEBI16977
ChEMBLCHEMBL12198
Therapeutic Targets DatabaseDAP000805
PharmGKBPA448055
IUPHAR720
Guide to Pharmacology720
HETALA
ATC CodesNot Available
AHFS CodesNot Available
PDB Entries
FDA labelNot Available
MSDSshow(71.9 KB)
Interactions
Drug InteractionsNot Available
Food InteractionsNot Available

Targets

1. Serine--pyruvate aminotransferase

Kind: protein

Organism: Human

Pharmacological action: unknown

Components

Name UniProt ID Details
Serine--pyruvate aminotransferase P21549 Details

References:

  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. Pubmed
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. Pubmed
  3. Salido EC, Li XM, Lu Y, Wang X, Santana A, Roy-Chowdhury N, Torres A, Shapiro LJ, Roy-Chowdhury J: Alanine-glyoxylate aminotransferase-deficient mice, a model for primary hyperoxaluria that responds to adenoviral gene transfer. Proc Natl Acad Sci U S A. 2006 Nov 28;103(48):18249-54. Epub 2006 Nov 16. Pubmed
  4. Amoroso A, Pirulli D, Florian F, Puzzer D, Boniotto M, Crovella S, Zezlina S, Spano A, Mazzola G, Savoldi S, Ferrettini C, Berutti S, Petrarulo M, Marangella M: AGXT gene mutations and their influence on clinical heterogeneity of type 1 primary hyperoxaluria. J Am Soc Nephrol. 2001 Oct;12(10):2072-9. Pubmed
  5. Pirulli D, Puzzer D, Ferri L, Crovella S, Amoroso A, Ferrettini C, Marangella M, Mazzola G, Florian F: Molecular analysis of hyperoxaluria type 1 in Italian patients reveals eight new mutations in the alanine: glyoxylate aminotransferase gene. Hum Genet. 1999 Jun;104(6):523-5. Pubmed

2. 4-aminobutyrate aminotransferase, mitochondrial

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: inhibitor

Components

Name UniProt ID Details
4-aminobutyrate aminotransferase, mitochondrial P80404 Details

References:

  1. Amadasi A, Bertoldi M, Contestabile R, Bettati S, Cellini B, di Salvo ML, Borri-Voltattorni C, Bossa F, Mozzarelli A: Pyridoxal 5’-phosphate enzymes as targets for therapeutic agents. Curr Med Chem. 2007;14(12):1291-324. Pubmed
  2. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. Pubmed

3. Kynureninase

Kind: protein

Organism: Human

Pharmacological action: unknown

Components

Name UniProt ID Details
Kynureninase Q16719 Details

References:

  1. Christensen M, Duno M, Lund AM, Skovby F, Christensen E: Xanthurenic aciduria due to a mutation in KYNU encoding kynureninase. J Inherit Metab Dis. 2007 Apr;30(2):248-55. Epub 2007 Mar 1. Pubmed
  2. Lima S, Khristoforov R, Momany C, Phillips RS: Crystal structure of Homo sapiens kynureninase. Biochemistry. 2007 Mar 13;46(10):2735-44. Epub 2007 Feb 15. Pubmed

4. Alanine--tRNA ligase, mitochondrial

Kind: protein

Organism: Human

Pharmacological action: unknown

Components

Name UniProt ID Details
Alanine--tRNA ligase, mitochondrial Q5JTZ9 Details

References:

  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. Pubmed
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. Pubmed
  3. Nagan MC, Beuning P, Musier-Forsyth K, Cramer CJ: Importance of discriminator base stacking interactions: molecular dynamics analysis of A73 microhelix(Ala) variants. Nucleic Acids Res. 2000 Jul 1;28(13):2527-34. Pubmed
  4. McClain WH, Gabriel K, Schneider J: Specific function of a G.U wobble pair from an adjacent helical site in tRNA(Ala) during recognition by alanyl-tRNA synthetase. RNA. 1996 Feb;2(2):105-9. Pubmed
  5. Buechter DD, Schimmel P: Minor groove recognition of the critical acceptor helix base pair by an appended module of a class II tRNA synthetase. Biochemistry. 1995 May 9;34(18):6014-9. Pubmed

5. 5-phosphohydroxy-L-lysine phospho-lyase

Kind: protein

Organism: Human

Pharmacological action: unknown

Components

Name UniProt ID Details
5-phosphohydroxy-L-lysine phospho-lyase Q8IUZ5 Details

References:

  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. Pubmed
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. Pubmed

6. Alanine aminotransferase 2

Kind: protein

Organism: Human

Pharmacological action: unknown

Components

Name UniProt ID Details
Alanine aminotransferase 2 Q8TD30 Details

References:

  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. Pubmed
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. Pubmed
  3. Yang RZ, Blaileanu G, Hansen BC, Shuldiner AR, Gong DW: cDNA cloning, genomic structure, chromosomal mapping, and functional expression of a novel human alanine aminotransferase. Genomics. 2002 Mar;79(3):445-50. Pubmed
  4. Jadhao SB, Yang RZ, Lin Q, Hu H, Anania FA, Shuldiner AR, Gong DW: Murine alanine aminotransferase: cDNA cloning, functional expression, and differential gene regulation in mouse fatty liver. Hepatology. 2004 May;39(5):1297-302. Pubmed
  5. Rajamohan F, Nelms L, Joslin DL, Lu B, Reagan WJ, Lawton M: cDNA cloning, expression, purification, distribution, and characterization of biologically active canine alanine aminotransferase-1. Protein Expr Purif. 2006 Jul;48(1):81-9. Epub 2006 Jan 30. Pubmed

7. Alanine aminotransferase 1

Kind: protein

Organism: Human

Pharmacological action: unknown

Components

Name UniProt ID Details
Alanine aminotransferase 1 P24298 Details

References:

  1. Miyashita Y, Dolferus R, Ismond KP, Good AG: Alanine aminotransferase catalyses the breakdown of alanine after hypoxia in Arabidopsis thaliana. Plant J. 2007 Mar;49(6):1108-21. Epub 2007 Feb 22. Pubmed
  2. Gray S, Wang B, Orihuela Y, Hong EG, Fisch S, Haldar S, Cline GW, Kim JK, Peroni OD, Kahn BB, Jain MK: Regulation of gluconeogenesis by Kruppel-like factor 15. Cell Metab. 2007 Apr;5(4):305-12. Pubmed
  3. Taracha E, Habrat B, Chrapusta SJ, Lehner M, Wislowska A, Woronowicz BT, Bogulas M, Charewicz J, Markuszewski C, Plaznik A: Combining markers of nephrotoxicity and hepatotoxicity for improved monitoring and detection of chronic alcohol abuse. Clin Chem Lab Med. 2006;44(12):1446-52. Pubmed
  4. Chen CH, Lee RP, Wu WT, Liao KW, Hsu N, Hsu BG: Fluvastatin ameliorates endotoxin induced multiple organ failure in conscious rats. Resuscitation. 2007 Jul;74(1):166-74. Epub 2007 Mar 13. Pubmed

8. Cysteine desulfurase, mitochondrial

Kind: protein

Organism: Human

Pharmacological action: unknown

Components

Name UniProt ID Details
Cysteine desulfurase, mitochondrial Q9Y697 Details

References:

  1. You D, Wang L, Yao F, Zhou X, Deng Z: A novel DNA modification by sulfur: DndA is a NifS-like cysteine desulfurase capable of assembling DndC as an iron-sulfur cluster protein in Streptomyces lividans. Biochemistry. 2007 May 22;46(20):6126-33. Epub 2007 May 1. Pubmed
  2. Zeng J, Zhang Y, Liu Y, Zhang X, Xia L, Liu J, Qiu G: Expression, purification and characterization of a cysteine desulfurase, IscS, from Acidithiobacillus ferrooxidans. Biotechnol Lett. 2007 Jul 28;. Pubmed

9. Proton-coupled amino acid transporter 1

Kind: protein

Organism: Human

Pharmacological action: unknown

Components

Name UniProt ID Details
Proton-coupled amino acid transporter 1 Q7Z2H8 Details

References:

  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. Pubmed
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. Pubmed
  3. Miyauchi S, Abbot EL, Zhuang L, Subramanian R, Ganapathy V, Thwaites DT: Isolation and function of the amino acid transporter PAT1 (slc36a1) from rabbit and discrimination between transport via PAT1 and system IMINO in renal brush-border membrane vesicles. Mol Membr Biol. 2005 Nov-Dec;22(6):549-59. Pubmed

10. Large neutral amino acids transporter small subunit 2

Kind: protein

Organism: Human

Pharmacological action: unknown

Components

Name UniProt ID Details
Large neutral amino acids transporter small subunit 2 Q9UHI5 Details

References:

  1. Broer S, Broer A, Hansen JT, Bubb WA, Balcar VJ, Nasrallah FA, Garner B, Rae C: Alanine metabolism, transport, and cycling in the brain. J Neurochem. 2007 Sep;102(6):1758-70. Epub 2007 May 14. Pubmed

11. Alanine--glyoxylate aminotransferase 2, mitochondrial

Kind: protein

Organism: Human

Pharmacological action: unknown

Components

Name UniProt ID Details
Alanine--glyoxylate aminotransferase 2, mitochondrial Q9BYV1 Details

References:

  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. Pubmed
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. Pubmed
  3. Okuno E, Ishikawa T, Kawai J, Kido R: Alanine:glyoxylate aminotransferase activities in liver of Suncus murinus (insectivora). Comp Biochem Physiol B. 1988;90(4):773-8. Pubmed
  4. Takada Y, Mori T, Noguchi T: The effect of vitamin B6 deficiency on alanine: glyoxylate aminotransferase isoenzymes in rat liver. Arch Biochem Biophys. 1984 Feb 15;229(1):1-6. Pubmed

12. Alanine--tRNA ligase, cytoplasmic

Kind: protein

Organism: Human

Pharmacological action: unknown

Components

Name UniProt ID Details
Alanine--tRNA ligase, cytoplasmic P49588 Details

References:

  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. Pubmed
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. Pubmed
  3. Nagan MC, Beuning P, Musier-Forsyth K, Cramer CJ: Importance of discriminator base stacking interactions: molecular dynamics analysis of A73 microhelix(Ala) variants. Nucleic Acids Res. 2000 Jul 1;28(13):2527-34. Pubmed
  4. McClain WH, Gabriel K, Schneider J: Specific function of a G.U wobble pair from an adjacent helical site in tRNA(Ala) during recognition by alanyl-tRNA synthetase. RNA. 1996 Feb;2(2):105-9. Pubmed
  5. Buechter DD, Schimmel P: Minor groove recognition of the critical acceptor helix base pair by an appended module of a class II tRNA synthetase. Biochemistry. 1995 May 9;34(18):6014-9. Pubmed

13. Neutral amino acid transporter A

Kind: protein

Organism: Human

Pharmacological action: unknown

Components

Name UniProt ID Details
Neutral amino acid transporter A P43007 Details

References:

  1. Zhang Z, Papageorgiou G, Corrie JE, Grewer C: Pre-steady-state currents in neutral amino acid transporters induced by photolysis of a new caged alanine derivative. Biochemistry. 2007 Mar 27;46(12):3872-80. Epub 2007 Feb 21. Pubmed
  2. Takasaki C, Miura E, Watanabe M: Segmental and complementary expression of L-serine biosynthetic enzyme 3-phosphoglycerate dehydrogenase and neutral amino acid transporter ASCT1 in the mouse kidney. Biomed Res. 2007 Apr;28(2):61-9. Pubmed
  3. Zhang Z, Grewer C: The sodium-coupled neutral amino acid transporter SNAT2 mediates an anion leak conductance that is differentially inhibited by transported substrates. Biophys J. 2007 Apr 1;92(7):2621-32. Epub 2007 Jan 19. Pubmed
  4. Pinho MJ, Pinto V, Serrao MP, Jose PA, Soares-da-Silva P: Underexpression of the Na+-dependent neutral amino acid transporter ASCT2 in the spontaneously hypertensive rat kidney. Am J Physiol Regul Integr Comp Physiol. 2007 Jul;293(1):R538-47. Epub 2007 May 2. Pubmed
  5. Wu Y, Shen D, Chen Z, Clayton S, Vadgama JV: Taxol induced apoptosis regulates amino acid transport in breast cancer cells. Apoptosis. 2007 Mar;12(3):593-612. Epub 2006 Dec 29. Pubmed

Transporters

1. Monocarboxylate transporter 10

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: inhibitor

Components

Name UniProt ID Details
Monocarboxylate transporter 10 Q8TF71 Details

References:

  1. Kim DK, Kanai Y, Chairoungdua A, Matsuo H, Cha SH, Endou H: Expression cloning of a Na+-independent aromatic amino acid transporter with structural similarity to H+/monocarboxylate transporters. J Biol Chem. 2001 May 18;276(20):17221-8. Epub 2001 Feb 20. Pubmed

Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on September 24, 2013 13:46